Concepedia

K. Hasegawa

KH

2

Publications

104

Citations

2

H-Index

2023

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

K. Hasegawa is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, cancer therapeutics, and cervical cancer.

Top concepts

Publications per year

2023–2024

2

Publications

2

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Toon Van Gorp, David Cibula, Weiguo Lv et al. · Annals of Oncology · 2024 · 64 citations

LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

Domenica Lorusso, Yang Xiang, K. Hasegawa et al. · Annals of Oncology · 2023 · 40 citations · Full text

, , +7

Rows per page

1–2 of 2